Plain-English translation of NCT06234579 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
The GALILEO study is watching how advanced lung cancer with an ALK gene change responds to standard treatments like alectinib, brigatinib, or lorlatinib. Researchers want to understand why some cancers stop responding to these medications over time, and what genetic changes happen as the cancer evolves. By following patients carefully and studying tumor samples, the study aims to better predict which treatments will work best for each person.
When people with this type of lung cancer are treated with targeted drugs, the cancer often develops resistance and stops responding. This study exists to understand exactly how and why this happens at the genetic level, so doctors can eventually predict resistance earlier and choose better treatment strategies.
You likely qualify if…
You likely don't qualify if…
You would be part of an observational study, meaning you would continue your regular cancer care and treatment rather than trying something new. Researchers would follow your progress, collect information about how you respond to the medication, and periodically take tissue or blood samples to study the genetic changes in your cancer. Your involvement would be tracked over time as you receive your standard treatment, allowing doctors to understand what happens as your cancer evolves.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Italy
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Enrollment target
~108 participants
Started
July 2021
Primary completion
March 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Emanuele Vita, MD
Fondazione Policlinico Universitario A Gemelli
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.